TScan Therapeutics, Inc.
Costs Associated with Exit or Disposal Activities · also 3.01, 5.02, 7.01, 8.01, 9.01 · Biological Products, (No Diagnostic Substances) · WALTHAM, MA · event 2026-08-27
Emerging growth company · FY2025 revenue $10.3M
“The Company also announced updated data from Cohort C of its Phase 1 ALLOHA study of TSC-101 in heme malignancies.”